+

WO2008012470A3 - Derives d'imidazolones substitues, preparation et utilisations - Google Patents

Derives d'imidazolones substitues, preparation et utilisations Download PDF

Info

Publication number
WO2008012470A3
WO2008012470A3 PCT/FR2007/051716 FR2007051716W WO2008012470A3 WO 2008012470 A3 WO2008012470 A3 WO 2008012470A3 FR 2007051716 W FR2007051716 W FR 2007051716W WO 2008012470 A3 WO2008012470 A3 WO 2008012470A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
imidazolone derivatives
derivatives
relates
present
Prior art date
Application number
PCT/FR2007/051716
Other languages
English (en)
Other versions
WO2008012470A2 (fr
Inventor
Edith Bouey
Christophe Masson
Karine Bertrand
Original Assignee
Genfit
Edith Bouey
Christophe Masson
Karine Bertrand
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US12/309,642 priority Critical patent/US20100004159A1/en
Priority to AU2007279135A priority patent/AU2007279135A1/en
Priority to EA200900211A priority patent/EA200900211A1/ru
Priority to NZ575011A priority patent/NZ575011A/en
Priority to CA002658625A priority patent/CA2658625A1/fr
Priority to MX2009000900A priority patent/MX2009000900A/es
Priority to BRPI0715326-0A priority patent/BRPI0715326A2/pt
Application filed by Genfit, Edith Bouey, Christophe Masson, Karine Bertrand filed Critical Genfit
Priority to EP07823633A priority patent/EP2049107A2/fr
Priority to JP2009521318A priority patent/JP2009544675A/ja
Publication of WO2008012470A2 publication Critical patent/WO2008012470A2/fr
Publication of WO2008012470A3 publication Critical patent/WO2008012470A3/fr
Priority to NO20090348A priority patent/NO20090348L/no
Priority to IL196671A priority patent/IL196671A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des dérivés d' imidazolones poly-substitués ayant des propriétés activatrices des PPAR et des propriétés antagonistes du récepteur ATl, les compositions pharmaceutiques les comprenant ainsi que leurs applications thérapeutiques dans les domaines de la santé humaine et animale. La présente invention a également trait à un procédé de préparation de ces dérivés.
PCT/FR2007/051716 2006-07-24 2007-07-24 Derives d'imidazolones substitues, preparation et utilisations WO2008012470A2 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
EP07823633A EP2049107A2 (fr) 2006-07-24 2007-07-24 Derives d'imidazolones substitues, preparation et utilisations
EA200900211A EA200900211A1 (ru) 2006-07-24 2007-07-24 Замещенные производные имидазолона, их получение и применение
NZ575011A NZ575011A (en) 2006-07-24 2007-07-24 Substituted imidazolone derivatives, preparation and uses
CA002658625A CA2658625A1 (fr) 2006-07-24 2007-07-24 Derives d'imidazolones substitues, preparation et utilisations
MX2009000900A MX2009000900A (es) 2006-07-24 2007-07-24 Derivados de imidazolonas sustituidas, preparacion y usos.
US12/309,642 US20100004159A1 (en) 2006-07-24 2007-07-24 Substituted imidazolone derivatives, preparations and uses
AU2007279135A AU2007279135A1 (en) 2006-07-24 2007-07-24 Substituted imidazolone derivatives, preparation and uses
BRPI0715326-0A BRPI0715326A2 (pt) 2006-07-24 2007-07-24 compostos derivados de imidazolonas polissubstituÍdas, composiÇço farmacÊutica e, uso de pelo menos um composto
JP2009521318A JP2009544675A (ja) 2006-07-24 2007-07-24 置換されたイミダゾロン誘導体、製造方法及び使用
IL196671A IL196671A0 (en) 2006-07-24 2009-01-22 Substituted imidazolone derivatives, preparation and uses
NO20090348A NO20090348L (no) 2006-07-24 2009-01-22 Substituerte imidazolonderivater, sammensetninger og anvendelser av samme, samt fremgangsmater for fremstilling av samme

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0606752A FR2903984B1 (fr) 2006-07-24 2006-07-24 Derives d'imidazolones substitues, preparation et utilisations
FR0606752 2006-07-24

Publications (2)

Publication Number Publication Date
WO2008012470A2 WO2008012470A2 (fr) 2008-01-31
WO2008012470A3 true WO2008012470A3 (fr) 2008-03-20

Family

ID=37843186

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/051716 WO2008012470A2 (fr) 2006-07-24 2007-07-24 Derives d'imidazolones substitues, preparation et utilisations

Country Status (16)

Country Link
US (1) US20100004159A1 (fr)
EP (1) EP2049107A2 (fr)
JP (1) JP2009544675A (fr)
KR (1) KR20090038469A (fr)
CN (1) CN101522192A (fr)
AU (1) AU2007279135A1 (fr)
BR (1) BRPI0715326A2 (fr)
CA (1) CA2658625A1 (fr)
EA (1) EA200900211A1 (fr)
FR (1) FR2903984B1 (fr)
IL (1) IL196671A0 (fr)
MX (1) MX2009000900A (fr)
NO (1) NO20090348L (fr)
NZ (1) NZ575011A (fr)
WO (1) WO2008012470A2 (fr)
ZA (1) ZA200901268B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
EP2552209A4 (fr) * 2010-03-26 2014-01-22 Merck Sharp & Dohme Nouveaux dérivés spiro d'imidazolone au titre d'antagonistes de récepteurs de glucagone, compositions, et méthodes pour leur utilisation
WO2011157827A1 (fr) 2010-06-18 2011-12-22 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012009226A1 (fr) * 2010-07-13 2012-01-19 Merck Sharp & Dohme Corp. Imidazolones substitués, compositions contenant ces composés, et procédés d'utilisation
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
RU2641003C2 (ru) * 2013-06-27 2018-01-15 ЭлДжи КЕМ, ЛТД. Биарильные производные в качестве агонистов gpr120
WO2015095011A1 (fr) 2013-12-17 2015-06-25 Janssen Pharmaceutica Nv Dérivé d'imidazoline-5-one utile en tant qu'inhibiteur de fas pour le traitement du cancer
CN105439946B (zh) * 2014-08-13 2018-02-02 益方生物科技（上海）有限公司 羧酸化合物及其制备方法和用途
CN104177298B (zh) * 2014-09-18 2018-10-02 湘潭大学 4,4-二取代-4,5-二氢-1h–咪唑-5-酮、衍生物及其合成方法
EP3799873A1 (fr) 2015-07-17 2021-04-07 Institut Pasteur Agent récepteur-stimulant 5-hydroxytryptamine1b destiné à être utilisé comme promoteur de l'autorenouvellement de cellules et/ou la différenciation par satellite
TW201713631A (zh) * 2015-09-11 2017-04-16 拉夸里亞創藥股份有限公司 作為trpm8拮抗劑之咪唑啉酮衍生物
EP3795563B1 (fr) 2016-03-31 2024-07-17 Oncternal Therapeutics, Inc. Analogues d'indoline et leurs utilisations
JP2019524723A (ja) 2016-07-15 2019-09-05 アンスティテュ・パストゥール 皮膚および／または毛の修復のための５−ヒドロキシトリプタミン１ｂ受容体刺激剤
CN113121394B (zh) * 2019-12-30 2022-11-08 中国药科大学 一种苯氧乙酸类衍生物的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003048130A2 (fr) * 2001-11-30 2003-06-12 Eli Lilly And Company Agonistes du recepteur active de proliferation du peroxisome
WO2004014308A2 (fr) * 2002-08-10 2004-02-19 Bethesda Pharmaceuticals, Inc. Nouveaux ligands ppar ne provoquant aucune retention de fluide, aucun oedeme ni aucune insuffisance cardiaque congestive
WO2004082621A2 (fr) * 2003-03-15 2004-09-30 Bethesda Pharmaceuticals, Inc. Nouveaux agonistes ppar, compositions pharmaceutiques et leurs utilisations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003048130A2 (fr) * 2001-11-30 2003-06-12 Eli Lilly And Company Agonistes du recepteur active de proliferation du peroxisome
WO2004014308A2 (fr) * 2002-08-10 2004-02-19 Bethesda Pharmaceuticals, Inc. Nouveaux ligands ppar ne provoquant aucune retention de fluide, aucun oedeme ni aucune insuffisance cardiaque congestive
WO2004082621A2 (fr) * 2003-03-15 2004-09-30 Bethesda Pharmaceuticals, Inc. Nouveaux agonistes ppar, compositions pharmaceutiques et leurs utilisations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BERNHART G A ET AL: "A NEW SERIES OF IMIDAZOLONES: HIGHLY SPECIFIC AND POTENT NONPEPTIDEAT1 ANTIOTENSIN II RECEPTOR ANTAGONISTS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 36, no. 22, 1993, pages 3371 - 3380, XP002064391, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
CN101522192A (zh) 2009-09-02
NZ575011A (en) 2011-12-22
KR20090038469A (ko) 2009-04-20
FR2903984B1 (fr) 2008-10-03
MX2009000900A (es) 2009-06-18
CA2658625A1 (fr) 2008-01-31
NO20090348L (no) 2009-04-24
ZA200901268B (en) 2010-04-28
IL196671A0 (en) 2009-11-18
WO2008012470A2 (fr) 2008-01-31
BRPI0715326A2 (pt) 2013-08-13
EA200900211A1 (ru) 2009-06-30
EP2049107A2 (fr) 2009-04-22
JP2009544675A (ja) 2009-12-17
AU2007279135A1 (en) 2008-01-31
FR2903984A1 (fr) 2008-01-25
US20100004159A1 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
WO2008012470A3 (fr) Derives d'imidazolones substitues, preparation et utilisations
IL274602B (en) Pharmaceutical tablets containing eltrombopag olamine, methods for their preparation and their use in the preparation of drugs for the treatment of thrombocytopenia
TNSN08326A1 (en) Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
WO2007016496A3 (fr) Dipipérazinyl cétones et analogues apparentés
WO2009003003A3 (fr) Composés de pipérazinyl oxoalkyl tétrahydro-bêta-carbolines et analogues apparentés
WO2007118963A3 (fr) Composes derives de n-(phenethyl)benzamide substitues, preparation et utilisations
IL189499A (en) Use of 2,4-diaminopyrimidines or 4-aminopyrimidines for the preparation of a medicament for the treatment of a respiratory disease mediated by a p2x3 or p2x2/3 receptor antagonist
WO2007146122A3 (fr) Tétrahydropyrido[3,4-d]pyrimidines et analogues associés
IL204052A (en) Annotation of 1,1,1 - Tripluoro - 2 - Hydroxy - 3 - Phenylpropane
IL215579A (en) Use of 1-benzyl-3-hydroxymethylindazole history to prepare medicinal products for the treatment of diseases based on the expression of 1-mcp, cx3cr1 and 40p
MY149854A (en) Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
WO2009039431A3 (fr) Amines spirocycliques aryl-condensées substituées
SI2176252T1 (sl) 2,3-dihidrobenzo(1,4)dioksin-2-ilmetilni derivati kot alfa2C antagonisti za uporabo v zdravljenju bolezni perifernega in centralnega živčnega sistema
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
PL2401263T3 (pl) Podstawione pochodne azotu, zawierająca pochodne kompozycja farmaceutyczna, i sposób leczenia choroby Parkinsona przy ich użyciu
WO2008087366A3 (fr) Derives de 3-phenyl-1-(phenylthienyl)propan-1-one et de 3-phenyl-1-(phenylfuranyl)propan-1-one substitues, preparation et utilisation
PL2238110T3 (pl) Pochodne 5,6-bisarylo-2-pirydyno-karboksamidu, ich wytwarzanie i ich zastosowanie terapeutyczne jako antagonistów receptora Urotensyny II
JO3319B1 (ar) مركبات 3- (ايميدازول) - بيرازولو (3,4 - b ) بيريدين
WO2007093365A3 (fr) Nouvelles arylthiénopyrimidinones à substitution aminoalcool, leur procédé de préparation et leur utilisation comme médicaments
IL203936A (en) HISTORY 4 - Pyrimidinsulfamide, Process for Preparation, Pharmaceutical Preparations Containing and Using it for Medication Preparation
MX2010009395A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procesos para preparacion de los mismos.
IL204126A (en) Derivatives of 1, 3 - dihydroisoindole, their preparation, use, drugs and kit containing them and intermediates
WO2008116663A3 (fr) Dérivés de tétrahydro-naphtalène-amine substitués par un hétérocyclyle, leur préparation et utilisation en tant que médicaments
IL213983A (en) Derivatives of pyridazinone that are converted into heteroaryl, their process, their pharmaceutical preparations and their use in the preparation of drugs
WO2007012479A3 (fr) Composes

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780035207.0

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2658625

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12009500188

Country of ref document: PH

Ref document number: MX/A/2009/000900

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 12309642

Country of ref document: US

Ref document number: 2009521318

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1177/DELNP/2009

Country of ref document: IN

Ref document number: 2007823633

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 575011

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 200900211

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2007279135

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 1020097003832

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0715326

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090123

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载